

ASX ANNOUNCEMENT

Appendix 4C – Quarterly Cash Flow Report

Highlights for the quarter ended 30th September 2018

- **Independent US-based biostatistician analyses PeriCoach version 3 real-world data.**
- **At the conclusion of the 8 Week Challenge, more than 75% of users have at least 80% reduction in volume and leakage episodes, a highly meaningful and significant improvement in continence symptoms.**
- **Real-world data analysis provides heightened insight into utilisation, treatment patterns and reported health outcomes for women managing urinary incontinence.**
- **Analytica signs manufacturing services agreement**
- **Cash balance at 30th September \$2,118k.**

31st October 2018: Analytica Ltd (ASX: ALT), manufacturer of the PeriCoach® system and the AutoStart® infusion system technologies has today released its Appendix 4C - Quarterly Cashflow report for period ending 31st September 2018.

Analysis of PeriCoach real-world data conducted by an independent biostatistician reveals significant improvements in pelvic floor strength in five weeks, and reduction in urine volume and leakage episodes in only three weeks. The post-approval allcomers observational study, reviewed women using the version 3 PeriCoach system.

PeriCoach version 3, released May 2017, comprises a state-of-the-art measuring system combined with a structured treatment programme. The market-leading features include real-time technique feedback to assist with proper pelvic floor muscle contraction, and force-sensors that measure the muscles that matter. New version 3 PeriCoach users are invited to participate in a structured exercise regime and record urinary habits in the app-based bladder diary.

More than 60% of v3 users who used the device and participate in a structured exercise regime for at least 3 weeks reported a highly significant reduction in leakage episodes (30% reduction, $p=.0059$) and volume (30% reduction, $p=.0017$) by week 3 and beyond. By week eight, more than 75% of the users have at least 80% improvement in both episodes and volume.

"These results from PeriCoach version 3 users are without a doubt clinically significant on top of being statistically significant.," states Chairman Dr. Michael Monsour. "As a clinician, I hear from women daily about their frustration in lack of change in continence symptoms after years of 'Kegels at home'. This echoes data that shows performing un-assisted pelvic exercises women report outcomes of 3% almost continent, 87% unchanged and 10% worse. PeriCoach provides the best of both worlds, clinical level guidance from the privacy of their own homes. Now, women can expect to have noticeable improvement in continence symptoms in just a few weeks."

"Real-world data analysis is invaluable in the e-health arena. This type of data truly demonstrates how consumers actually interact with a product as well as how a product will work outside the confines of a



clinical trial," said Geoff Daly, CEO of Analytica Ltd. "PeriCoach version 3 gives us the power to analyse the user experience while leveraging our keen understanding of key clinical outcome measures. All the enhancements and investment into the version 3 PeriCoach have been designed with this focus. The biggest success here is that women and clinicians can be confident in expectations for improvement in continence when pelvic floor rehabilitation is supported by PeriCoach."

Analytica has signed a manufacturing services agreement with another Australian-based contract manufacturer. Analytica has spent several months negotiating this agreement which defines roles and responsibilities for the production and quality systems of both companies.

The systems created with the new contract manufacturer will provide flexibility in product and process changes and the supply chain overall. The new manufacturer is ISO13485 certified and is US Quality System Regulation compliant and has experience growing medical devices from concept through to mass-manufacture overseas. The processes developed can be scaled, moved or duplicated, which adds value to a potential acquirer if they intend to integrate the PeriCoach production into their own manufacturing facilities offshore. The contract manufacturer also has a strong product development team which can be used to augment Analytica's own capability to drive further product enhancements, particularly in cost-of-goods reductions.

Analytica expects to re-register its establishments with the USFDA and resume supply of the PeriCoach to the US this quarter.

Receipts from sales of PeriCoach in Analytica's key markets of Australia, the UK and the US totalled \$11k, due to withdrawal of PeriCoach from the US until manufacturing is re-established. Marketing activity is focused on recruitment for data collection and feature development. Research & development expenditure was \$289k, dominated by expenditure on the PeriCoach "big data" project, the largest and most comprehensive pelvic floor muscle exercise database and analysis platform in the world. \$276k was incurred on staff costs and administration costs of \$119k.

The company has access to a \$400k loan facility. Directors are monitoring capital requirements to ensure the company has adequate cash to continue development and undertake partnering negotiations of the PeriCoach and the AutoFlush and AutoStart burette technologies. The Company continues to have the financial support of its major shareholders.

As outlined in the Chairman's address to the Annual General Meeting in November 2017, Analytica is achieving its goals set out at the Annual General meeting 2016 of being deal-ready. This quarter demonstrates further strong progress to the Company strategy; build a product that is best in class, gather evidence that the product performance is exceptional, and actively pursue partnering opportunities.

For more information, please contact: investorrelations@analyticamedical.com

For more information about the PeriCoach System, visit: www.PeriCoach.com

For more information about Analytica, visit www.AnalyticaMedical.com

Follow us on:





About Analytica Limited

Analytica's lead product is the PeriCoach® System – an e-health treatment system for women who suffer Stress Urinary Incontinence. This affects 1 in 3 women worldwide and is mostly caused by trauma to the pelvic floor muscles as a result of pregnancy, childbirth and menopause.

PeriCoach comprises a device, web portal and smartphone app. The device evaluates activity in pelvic floor muscles. This information is transmitted to a smartphone app and can be loaded to a cloud database where physicians can monitor patient progress via web portal. This novel system enables physicians to remotely determine if a woman is performing her pelvic floor exercises and if these are improving her condition. Strengthening of the pelvic floor muscles can also potentially improve sexual sensation or satisfaction and orgasm potential in some women.

PeriCoach has regulatory clearance in Australia, and has CE mark and USFDA 510(k) clearance. The product is available for sale from pericoach.com in Australia and New Zealand, UK and Ireland.

Appendix 4C

Quarterly report for entities subject to Listing Rule 4.7B

Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10, 01/09/16

Name of entity

Analytica Ltd

ABN

12 006 464 866

Quarter ended ("current quarter")

September 2018

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (3 months) \$A'000
1. Cash flows from operating activities			
1.1 Receipts from customers	11	11	
1.2 Payments for			
(a) research and development	(289)	(289)	
(b) product manufacturing and operating costs	(1)	(1)	
(c) advertising and marketing	(47)	(47)	
(d) leased assets			
(e) staff costs	(276)	(276)	
(f) administration and corporate costs	(119)	(119)	
1.3 Dividends received (see note 3)			
1.4 Interest received	7	7	
1.5 Interest and other costs of finance paid			
1.6 Income taxes paid			
1.7 Government grants and tax incentives			
1.8 Other (provide details if material)	5	5	
1.9 Net cash from / (used in) operating activities	(709)	(709)	
2. Cash flows from investing activities			
2.1 Payments to acquire:			
(a) property, plant and equipment	(1)	(1)	
(b) businesses (see item 10)			

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (3 months) \$A'000
	(c) investments		
	(d) intellectual property		
	(e) other non-current assets		
2.2	Proceeds from disposal of:		
	(a) property, plant and equipment		
	(b) businesses (see item 10)		
	(c) investments		
	(d) intellectual property		
	(e) other non-current assets		
2.3	Cash flows from loans to other entities		
2.4	Dividends received (see note 3)		
2.5	Other (provide details if material)		
2.6	Net cash from / (used in) investing activities	(1)	(1)

3.	Cash flows from financing activities		
3.1	Proceeds from issues of shares		
3.2	Proceeds from issue of convertible notes		
3.3	Proceeds from exercise of share options		
3.4	Transaction costs related to issues of shares, convertible notes or options	(13)	(13)
3.5	Proceeds from borrowings		
3.6	Repayment of borrowings		
3.7	Transaction costs related to loans and borrowings		
3.8	Dividends paid		
3.9	Other (provide details if material)		
3.10	Net cash from / (used in) financing activities	(13)	(13)

4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of quarter/year to date	2,841	2,841
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(709)	(709)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(1)	(1)
4.4	Net cash from / (used in) financing activities (item 3.10 above)	(13)	(13)

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (3 months) \$A'000
4.5	Effect of movement in exchange rates on cash held		
4.6	Cash and cash equivalents at end of quarter	2,118	2,118

5. Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1 Bank balances	2,118	2,841
5.2 Call deposits		
5.3 Bank overdrafts		
5.4 Other (provide details)		
5.5 Cash and cash equivalents at end of quarter (should equal item 4.6 above)	2,118	2,841

6. Payments to directors of the entity and their associates

- 6.1 Aggregate amount of payments to these parties included in item 1.2
- 6.2 Aggregate amount of cash flow from loans to these parties included in item 2.3
- 6.3 Include below any explanation necessary to understand the transactions included in items 6.1 and 6.2

**Current quarter
\$A'000**

96
0

7. Payments to related entities of the entity and their associates

- 7.1 Aggregate amount of payments to these parties included in item 1.2
- 7.2 Aggregate amount of cash flow from loans to these parties included in item 2.3
- 7.3 Include below any explanation necessary to understand the transactions included in items 7.1 and 7.2

**Current quarter
\$A'000**

8. Financing facilities available <i>Add notes as necessary for an understanding of the position</i>	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
8.1 Loan facilities	400	0
8.2 Credit standby arrangements		
8.3 Other (please specify)		
8.4 Include below a description of each facility above, including the lender, interest rate and whether it is secured or unsecured. If any additional facilities have been entered into or are proposed to be entered into after quarter end, include details of those facilities as well.		

9. Estimated cash outflows for next quarter	\$A'000
9.1 Research and development	250
9.2 Product manufacturing and operating costs	40
9.3 Advertising and marketing	50
9.4 Leased assets	
9.5 Staff costs	290
9.6 Administration and corporate costs	160
9.7 Other (provide details if material)	
9.8 Total estimated cash outflows	790

10. Acquisitions and disposals of business entities (items 2.1(b) and 2.2(b) above)	Acquisitions	Disposals
10.1 Name of entity		
10.2 Place of incorporation or registration		
10.3 Consideration for acquisition or disposal		
10.4 Total net assets		
10.5 Nature of business		

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Sign here:
(Director)

Date:31st October 2018..

Print name: R. Mangelsdorf

Notes

1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity that wishes to disclose additional information is encouraged to do so, in a note or notes included in or attached to this report.
2. If this quarterly report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.